Xeris Biopharma Holdings Inc. (XERS), headquartered in Chicago, Illinois, is a prominent name in the field of pharmaceuticals, specializing in the development and commercialization of innovative, ready-to-use, and patient-friendly injectable and infusible drug formulations. The company’s proprietary XeriSol™ and XeriJect™ formulation technologies allow for the creation of ready-to-use liquid formulations of drugs that conventionally require reconstitution, refrigeration, constant agitation, or dilution.
Xeris Biopharma is well renowned for its novel approach to treating hypoglycemia, a critical condition often encountered in people living with diabetes. The company has shown its prowess in the industry by being the first to commercialize a ready-to-use, room-temperature stable glucagon, Gvoke®, for the emergency treatment of severe hypoglycemia. Gvoke® is available in both prefilled syringe (PFS) and autoinjector formats, providing fast and reliable treatment options for patients and caregivers in need.
Furthermore, XER-S3, Xeris’s developmental drug for the treatment of congenital hyperinsulinism, is in its Phases 2 and 3 and will further solidify its position as a market leader, providing pioneering solutions for those affected with this rare condition. Xeris’s commitment to deliver innovative and convenient drugs extends to other areas too, with diverse products under development in several therapeutic areas including epilepsy, adrenal insufficiency, and hypoglycemia.
Xeris Biopharma Holdings, Inc. operates on principles of developing breakthrough products which are patient-centric and bring convenience and effectiveness together. With a cutting-edge proprietary technology and an unyielding dedication to innovation, Xeris continues to strive for improving the lives of people with serious, chronic conditions and acute care needs.
The stock market recognizes Xeris Biopharma under the ticker symbol “XERS” on the NASDAQ Exchange. With a steady focus on its various research and development initiatives, Xeris has been able to secure its position in the competitive pharmaceuticals market, and continues on its dedicated path towards bringing effective, easy-to-use medication closer to those who need it. With robust growth strategies and continuous advancements in its proprietary technologies, Xeris Biopharma holds an optimistic future in the industry.